Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + ...
Pelareorep combined with modified FOLFIRINOX, with or without Tecentriq, shows an acceptable safety profile in metastatic PDAC patients. All patients experienced side effects, with some severe cases, ...
Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback